Cold sores can’t be cured because the virus that causes them, herpes simplex virus type 1 (HSV-1), hides inside your nerve cells in a dormant form that no existing medication can reach or destroy. Once you’re infected, the virus essentially becomes a permanent resident in your body, retreating to a place where both your immune system and antiviral drugs are powerless against it. Roughly 3.7 billion people worldwide under age 50 carry HSV-1, making this one of the most common and persistent infections on the planet.
Where the Virus Hides
After your first cold sore outbreak, HSV-1 travels along nerve fibers and settles into a cluster of nerve cells near your jaw called the trigeminal ganglion. Once there, the virus stops replicating and enters a dormant state called latency. During latency, the virus stores its genetic material as a small circular loop of DNA inside the nerve cell’s nucleus. This loop sits separately from your own DNA, quietly producing only a single type of molecule called a latency-associated transcript, or LAT, which helps the virus stay hidden and stable.
This is a critical distinction from some other viruses. HIV, for example, splices its genetic code directly into your chromosomes, which creates different challenges. HSV-1 keeps its DNA separate, like a stowaway hiding in a lifeboat. It doesn’t alter your genes, but it also doesn’t expose itself to the cell’s normal housekeeping processes that might clear it out. The virus can sit in this state for decades, producing almost nothing that would alert your immune system to its presence.
Why Your Immune System Can’t Finish the Job
Your immune system is actually quite good at fighting active cold sore outbreaks. Immune cells swarm to the site of a blister, kill infected skin cells, and eventually bring the outbreak under control. But latent virus in nerve cells is a different problem entirely.
HSV-1 has evolved multiple strategies to dodge immune detection. During active infection, it produces proteins that interfere with the signaling molecules your cells use to flag themselves as infected. Normally, infected cells display fragments of the invader on their surface so that immune cells can recognize and kill them. HSV-1 disrupts this display system and also blocks other branches of immune defense, including antibodies and natural killer cells. During latency, the problem is even worse: the virus is barely producing anything at all, so there’s almost nothing for the immune system to detect. A nerve cell harboring dormant HSV-1 looks, for all practical purposes, like a healthy nerve cell.
Why Antiviral Medications Fall Short
The antiviral drugs used for cold sores work by interrupting viral replication. They block an enzyme the virus needs to copy its DNA. This makes them effective only when the virus is actively multiplying, which happens in skin cells during an outbreak, not in the nerve cells where the virus sleeps.
Because the latent virus isn’t replicating, these drugs have no target to hit. As researchers at Fred Hutchinson Cancer Center have noted, antivirals are not effective against the latent reservoir. Even for active outbreaks, the drugs have significant limitations: they require large, consistent doses, often fail to fully control symptoms, and a growing number of patients are developing resistance to them. The medications can shorten an outbreak and reduce its severity, but they cannot prevent the virus from retreating back into nerve cells when the episode ends.
What Triggers a Flare-Up
The virus doesn’t stay dormant forever. Periodically, something nudges it out of latency, and it begins replicating again. The reactivated virus travels back down the nerve fibers to the skin, where it causes a new cold sore or, in many cases, sheds invisibly without producing any visible sore at all.
Common triggers include UV light exposure (sunburn on the lips is a classic one), physical or emotional stress, fever, hormonal shifts, and immune suppression from illness or medication. At the molecular level, reactivation begins when signals from the host cell lift the suppression that keeps the viral DNA quiet. The exact cascade is complex and involves both viral and human molecules, which is part of why it’s so difficult to prevent.
Even when you feel perfectly fine and have no visible sore, the virus can be active. Studies that swabbed people’s mouths daily found that HSV-1 carriers shed virus on a median of about 9% of days. Asymptomatic shedding, meaning virus detected with no sore present, occurred on roughly 7% of days. Some individuals shed on nearly half of all days tested. This invisible shedding is one reason the virus spreads so efficiently through the population.
The Challenge of Reaching Nerve Cells
Even if a drug could theoretically destroy latent HSV-1 DNA, getting it to the right place is an enormous hurdle. The trigeminal ganglion sits deep inside the skull, and nerve cells are among the longest-lived cells in the body. They’re also protected by barriers that limit what substances can reach them. Any treatment designed to eliminate latent HSV-1 would need to enter the nervous system, find the specific neurons harboring viral DNA (among billions of uninfected ones), and destroy or edit the viral genome without damaging the nerve cell itself. Killing the neurons is not an option, since losing sensory nerve cells in the face could cause permanent numbness or other neurological problems.
Gene Editing as a Potential Solution
The most promising approach to actually curing cold sores involves using gene-editing tools like CRISPR to cut the viral DNA apart while it sits dormant inside nerve cells. Rather than waiting for the virus to wake up and then attacking it with antivirals, this strategy goes after the sleeping virus directly.
In laboratory studies, researchers have used delivery vehicles designed to enter neurons and carry CRISPR components that target essential viral genes. When tested in cell cultures and three-dimensional tissue models that mimic latent infection, these tools significantly reduced viral rebound, meaning far less virus reactivated after treatment. The results suggest that editing the viral genome can shrink the latent reservoir, potentially to the point where reactivation no longer occurs.
This work is still in early stages. The biggest remaining challenges are delivery (getting enough of the editing machinery into enough nerve cells in a living person) and safety (ensuring the CRISPR tools don’t accidentally cut human DNA). But the proof of concept is solid, and several research groups are actively working toward animal and eventually human trials.
Where Vaccines Stand
A vaccine that prevents HSV-1 infection or suppresses reactivation would be another route to solving the cold sore problem, but progress has been frustrating. Multiple candidates have entered clinical trials over the past two decades, and most have failed or produced disappointing results. GlaxoSmithKline’s Simplirix vaccine showed 58% protection against genital HSV-1 disease but did not protect against HSV-2. Genocea’s GEN-003 and Vical’s VCL-HB01 both produced unsatisfactory results in phase 2 trials and were abandoned.
Several candidates are still in active development. Moderna is testing an mRNA-based vaccine (mRNA-1608) in phase 1/2 trials, which represents a newer technological approach. Rational Vaccines has a live-attenuated candidate called RVx201 in phase 1/2 trials, and Anteris Technologies is running a phase 2 trial for COR-1, a DNA-based vaccine. Sanofi Pasteur’s HSV529, a replication-defective vaccine, is also in phase 2. None are close to approval, but the pipeline is more active than it has been in years.
The core difficulty with HSV vaccines is that even natural infection doesn’t produce immunity strong enough to prevent reactivation. Your body mounts a robust immune response to HSV-1, yet the virus persists anyway. A vaccine has to somehow do better than what natural immunity already achieves, which is a high bar that helps explain why so many candidates have failed.